LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
XFOR
X4 Pharmaceuticals, Inc.
There isn't enough reported data to score XFOR yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
XFOR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
XFOR's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
XFOR PE Valuation
XFOR has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
XFOR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect XFOR's revenue to grow, with its earnings and profitability holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus XFOR down 662%.
XFOR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$10.12 | -$8.32 |
| Q2 2025 | -$14.83 | -549% |
| Q1 2025 | $2.14 | +$22.24 |
| Q4 2024 | -$5.70 | +$11.40 |
| Q3 2022 | -$83.10 | +$27.90 |
| Q2 2022 | -$98.10 | +$16.20 |
| Q1 2022 | -$102.30 | +$12.60 |
| Q4 2021 | -$119.70 | -$27.00 |
XFOR is still losing money, but far less than before: $10.12 per share over the past year, against $119.70 at its worst in late 2021.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over XFOR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over XFOR on profitability, with a higher operating margin.
XFOR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.8M | +79% |
| Q2 2026 | $2.4M | +38% |
| Q1 2026 | $2.5M | +178% |
| Q4 2025 | $2.2M | +53% |
| Q3 2025 | $1.6M | +180% |
| Q2 2025 | $1.7M | +210% |
XFOR's revenue has grown year over year for 10 quarters in a row: $3M last quarter, up 79% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -714% | +1043 points |
| Q2 2026 | -683% | +821 points |
| Q1 2026 | -812% | +237 points |
| Q4 2025 | -1077% | +1413 points |
| Q3 2025 | -1757% | +4404 points |
| Q2 2025 | -1504% | -14133 points |
| Q1 2025 | -1049% | N/A |
| Q4 2024 | -2491% | N/A |
XFOR's operating margin was −714% last quarter, up 1043 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over XFOR on cash generation, producing positive trailing cash flow while its opponent burns cash.
XFOR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$20.2M | +$7.6M |
| Q2 2026 | -$20.8M | +$9.1M |
| Q1 2026 | -$19.6M | -$7.2M |
| Q4 2025 | -$15.5M | +$17.5M |
| Q3 2025 | -$27.8M | +$6.3M |
| Q2 2025 | -$29.9M | +$34.1M |
| Q1 2025 | -$12.4M | +$21.3M |
| Q4 2024 | -$33M | -$5.3M |
XFOR has burned cash in almost every quarter: −$76M over the past year, against −$103M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over XFOR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
XFOR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +180K shares |
| 1 year | +1607% | +119M shares |
| 3 years | +2149% | +121M shares |
| 5 years | +18192% | +126M shares |
| Available history | +18865% | +126M shares |
XFOR has 127M diluted shares, up 1607% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2023 | $443,000 |
| Q4 2022 | — |
| Q4 2021 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
XFOR Net Leverage
XFOR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
XFOR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 34.5 | Neutral |
XFOR's weekly RSI is 44 (neutral) and its Stochastic is 35 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
XFOR PE vs Healthcare Sector
| Metric | XFOR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XFOR has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over XFOR on trend strength, trading above more of its moving averages.
XFOR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.04 | 4.3% above |
| 20 week MA | $3.63 | 13% below |
| 50 week MA | $3.81 | 17% below |
| 100 week MA | $5.35 | 41% below |
| 200 week MA | $18.2 | 83% below |
XFOR has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 83% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over XFOR on returns for 2026, with the stronger performance.
XFOR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $325.8 | $210.3 | -35% |
| 2021 | $210.3 | $74.1 | -65% |
| 2022 | $74.1 | $25.8 | -65% |
| 2023 | $25.8 | $25.2 | -2.6% |
| 2024 | $25.2 | $24.1 | -4.1% |
| 2025 | $24.1 | $4.50 | -81% |
| 2026 YTD | $4.50 | $3.17 | -30% |
XFOR has finished every year since 2020 lower, and it's down 30% so far in 2026.